Alethio Therapeutics Raises $90M for Blood Cancer Trials

Alethio Therapeutics is financing a sequence of clinical questions about a protein called G6B. The Oxford spin-out’s $90M Series A, announced on November 5, 2026, is intended to take its lead blood-cancer programme through early human studies, turning patient-derived research into a development plan with named milestones.

Sofinnova Partners and RA Capital co-led the round, with founding investor Oxford Science Enterprises, Cancer Research Horizons and the University of Oxford also participating. For Alethio Therapeutics, the financing concentrates resources on essential thrombocythaemia, or ET, while supporting a broader pipeline for myeloproliferative neoplasms. Its clinical ambitions will take the company into a different relationship with the disease that its academic founders have spent years investigating.

What the $90M Series A is intended to fund

Alethio’s financing announcement describes an oversubscribed round and a specific use of proceeds: advance ATX-011 through Phase 1/2a studies in ET, toward Phase 3 readiness, and progress additional programmes toward investigational new drug submissions. The company reported the financing as $90M, equivalent to £67M. That is the disclosed Series A amount, without an inferred valuation or a claim about lifetime capital raised.

ATX-011 is a monoclonal antibody directed at G6B. Alethio lists the programme at the IND-enabling stage, the preparatory work supporting a move toward clinical testing. The planned studies remain future work; the financing announcement supplies no human efficacy result or completed Phase 1/2a trial.

The scope of the round matters because it names a development destination beyond the first experiment in people. Financing a programme through a planned early clinical sequence allows researchers and investors to organise around the questions that sequence must answer. Safety, biological activity and the programme’s eventual therapeutic value will have to emerge from the work itself, with regulatory review shaping the route forward.

Graziano Seghezzi, managing partner at Sofinnova Partners, and Maxwell DeNies of RA Capital join Alethio’s board in conjunction with the funding. Their appointments bring the new co-leads into the governance of those development choices. Oxford Science Enterprises remains involved after backing the company’s earlier formation.

Why a platelet target carries a wider ambition

ET is a blood cancer associated with excessive platelet production and increased risks that include thrombosis. Alethio’s pipeline description explains its interest in G6B through the protein’s relationship with platelets, the megakaryocytes that produce them, and disease-driving stem cells. ATX-011 is designed to influence platelet clearance by binding the target.

The company’s larger hypothesis is that a target associated with the diseased cell population could support treatment across different underlying driver mutations. That gives G6B a role in a broader MPN research strategy, rather than tying the entire programme to a single mutation-defined group. The potential reach comes from the proposed biology; clinical benefit remains an outcome to investigate.

Alethio reports target validation using samples from more than 100 MPN patients. Those samples provide material for studying disease and evaluating targets, and the number should be read in that research context. They are not 100 patients successfully treated with ATX-011.

The pipeline also separates the lead antibody from a G6B antibody-drug conjugate and a programme directed at mutant calreticulin. These have their own development stages and intended applications. Results from one approach cannot be silently transferred to another simply because the programmes share a company, a discovery engine or part of their biological rationale.

The Oxford history behind the clinical transition

Professors Adam Mead and Beth Psaila founded the business from University of Oxford research into blood cancers. Companies House records its incorporation in July 2021 and its former name, Alethiomics Limited, which remained in use until October 2025. The identity matters when tracing earlier research and investment: Alethiomics is part of this company’s history, rather than a separate venture with a similar name.

Oxford’s BioEscalator account documents the company’s move to Abingdon Science Park in 2025 and the seed backing from Oxford Science Enterprises that preceded it. The account provides an institutional record of the company’s development before this Series A. The new investors are joining an enterprise whose university and early-investor relationships have continued through the change of name and location.

The current leadership team includes CEO Rohit Batta, CSO Ed Ainscow and CDO Steve Coats. Batta’s company biography describes experience across rare-disease development, including roles at Ferring Ventures, Vicore Pharma and GSK. Psaila remains a founder and board observer, and Mead remains identified as a founder.

That combination gives the company two kinds of continuity: academic knowledge of the disease and executives responsible for moving a drug programme through development. Each has a different job as the clinical programme takes shape. Discovering a useful biological feature and deciding how to study an intervention in people belong to the same enterprise, with different evidence attached to each decision.

ARTEMIS gives the company work beyond one candidate

Alethio describes ARTEMIS as a discovery engine integrating patient-derived data, multi-omics, machine learning and disease-relevant organoid models. Its purpose is to identify and validate targets grounded in human disease biology. The commercial significance is the possibility of generating successive programmes from an organised research base, rather than depending entirely on one isolated discovery.

That is an interpretation of the company’s development model, not a forecast of pipeline productivity. Alethio has disclosed multiple programmes at different stages, but it has not supplied a comparable commercial revenue record, an approved product or clinical results establishing the platform’s eventual yield. The useful evidence today is narrower and more concrete: a lead candidate, specified early-study objectives and additional targets under development.

For investors following funding announcements, the relationship between platform breadth and clinical focus is the consequential choice here. A discovery engine can create several directions to pursue, while a clinical programme requires sustained attention to a particular indication and intervention. Alethio’s financing puts ET and ATX-011 at the front of that work while preserving resources for the programmes behind them.

Mead and Psaila’s patient-derived science now sits inside a company preparing to study its intervention in people. Batta and the expanded board will be making development decisions around that transition, with the first clinical questions about ATX-011 carrying consequences for the research programmes still following it.